Discovery of Macrocyclic Peptide Inhibitors Targeting MYC Oncoprotein via mRNA Display
Pharmaceuticals · 22.06.2026 · 19 (6) · 967
DOI: 10.3390/ph19060967 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 22.06.2026. Verfasst von Jinzhu Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Hangzhou Institute for Advanced Study, Research Funds of Hangzhou Institute for Advanced Study, UCAS.
Abstract (Originalsprache)
Background/Objectives: mRNA display technology has emerged as a powerful platform for discovering macrocyclic peptides against intractable proteins. However, direct screening against the “undruggable” transcription factor MYC using this approach remains largely unexplored. In this study, we aimed to integrate tyrosinase-mediated cyclization with mRNA display to identify novel macrocyclic peptide inhibitors targeting MYC.
Methods
We performed mRNA display combined with tyrosinase-mediated cyclization to generate macrocyclic peptides targeting MYC. Antiproliferative activity was assessed in MYC-dependent tumor cells using CCK8 assay. C-terminal fusions with a TAT-derived cell-penetrating peptide were generated to enhance cell membrane permeability. Binding affinities were measured by bio-layer interferometry (BLI). MYC transcriptional activity was evaluated by RNA sequencing (RNA-seq) analysis of canonical MYC target genes.
Results
The identified macrocyclic peptides exhibited potent antiproliferative activity against MYC-dependent tumor cells, with half-maximal inhibitory concentration (IC50) values in the micromolar range. Fusion with the TAT peptide improved antiproliferative potency, yielding IC50 values of 1–3 μM in MYC-dependent cell lines. BLI assays confirmed dose-dependent binding of the peptides to MYC, with dissociation constants (Kd) in the micromolar range. Furthermore, RNA-seq analysis revealed significant downregulation of canonical MYC target genes upon treatment with the TAT-fusion macrocyclic peptide, indicating specific suppression of MYC transcriptional activity.
Conclusions
This work establishes the feasibility of using mRNA display to target the “undruggable” protein MYC and identifies a panel of macrocyclic peptides as promising lead candidates for further optimization toward targeted therapies for MYC-driven cancers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.
- Shenzhen Sungening Biological Co., Ltd., Shenzhen 518172, China.
- School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
ORCID-Profile: Jinzhu Chen, Chenguang Yuan, Qiurong Ding, Yan Chen
Förderung
- National Natural Science Foundation of China
- Hangzhou Institute for Advanced Study
- Research Funds of Hangzhou Institute for Advanced Study, UCAS
Zitieren
APA
Chen, J., Li, F., Yuan, C., Geng, X., Zhang, Y., Ding, Q., & Chen, Y. (2026). Discovery of Macrocyclic Peptide Inhibitors Targeting MYC Oncoprotein via mRNA Display. Pharmaceuticals, 19(6), 967. https://doi.org/10.3390/ph19060967
Vancouver
Chen J, Li F, Yuan C, Geng X, Zhang Y, Ding Q, et al. Discovery of Macrocyclic Peptide Inhibitors Targeting MYC Oncoprotein via mRNA Display. Pharmaceuticals. 2026;19(6):967. doi:10.3390/ph19060967
BibTeX
@article{Chen2026,
author = {Chen, Jinzhu and Li, Fanglin and Yuan, Chenguang and Geng, Xiaoling and Zhang, Yu and Ding, Qiurong and Chen, Yan},
title = {Discovery of Macrocyclic Peptide Inhibitors Targeting MYC Oncoprotein via mRNA Display},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {6},
pages = {967},
doi = {10.3390/ph19060967}
}
EUVIMED